PolyPid Ltd. (PYPD)

NASDAQ: PYPD · IEX Real-Time Price · USD
5.53 -0.06 (-1.07%)
Jan 18, 2022 1:37 PM EST - Market open
Market Cap103.72M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out18.76M
EPS (ttm)-2.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,566
Open5.46
Previous Close5.59
Day's Range5.45 - 5.56
52-Week Range5.40 - 16.50
Betan/a
AnalystsBuy
Price Target24.00 (+334.0%)
Earnings DateNov 10, 2021

About PYPD

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

IndustryBiotechnology
IPO DateJun 26, 2020
Employees65
Stock ExchangeNASDAQ
Ticker SymbolPYPD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for PolyPid stock is "Buy." The 12-month stock price forecast is 24.00, which is an increase of 334.00% from the latest price.

Price Target
$24.00
(334.00% upside)
Analyst Consensus: Buy

News

PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D.

Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment

2 weeks ago - GlobeNewsWire

PolyPid Announces Planned CEO Transition

Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022 Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022

2 weeks ago - GlobeNewsWire

PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two Months Thereafter Company Continues to Expect that the Last Patient Wil...

2 months ago - GlobeNewsWire

Does PolyPid Ltd. (PYPD) Have the Potential to Rally 166% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 165.8% in PolyPid Ltd. (PYPD). While the effectiveness of this highly sought-after metric is questionable, the po...

2 months ago - Zacks Investment Research

PolyPid Appoints New Oncology Advisory Board Member

Company is Scheduled to Conduct Pre-IND Meeting with the U.S. FDA Later This Month and Potentially Initiate Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors in 2022 Company is Scheduled to Conduct ...

2 months ago - GlobeNewsWire

PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX 100  in Abdominal Surgery

2 months ago - GlobeNewsWire

PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021

PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered,...

2 months ago - GlobeNewsWire

PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor

PolyPid Ltd (NASDAQ: PYPD) has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. OncoPLEX is designed to provide cont...

4 months ago - Benzinga

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

PETAH TIKVA, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release thera...

4 months ago - GlobeNewsWire

PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

•  Recruitment Progressing as Planned with Over 3 00 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100  in Abdominal Surgery

5 months ago - GlobeNewsWire

PolyPid Presents today at The Raymond James Human Health Innovation Conference

Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT

6 months ago - GlobeNewsWire

PolyPid to Present at Upcoming Healthcare Investor Conferences

PETAH TIKVA, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-...

7 months ago - GlobeNewsWire

PolyPid's Single Pivotal Study Sufficient To Support Potential Approval Of D-PLEX100 For Infections After Colorectal ...

PolyPid Ltd (NASDAQ: PYPD) has received written responses from the FDA to a Type B meeting request that the company submitted regarding its development plan for its lead candidate, D-PLEX100. The FDA in...

7 months ago - Benzinga

PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update

• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery

8 months ago - GlobeNewsWire

PolyPid to Participate in Upcoming Investor Conferences

PETAH TIKVA, Israel, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, e...

10 months ago - GlobeNewsWire

PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

PETAH TIKVA, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-...

11 months ago - GlobeNewsWire

PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021

PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-...

11 months ago - GlobeNewsWire

PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program

Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemothe...

1 year ago - GlobeNewsWire

PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery ...

Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021

1 year ago - GlobeNewsWire

PolyPid to Host Key Opinion Leader Call Discussing D-PLEX₁₀₀ and the Prevention of Surgical Site Infections

PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged...

1 year ago - GlobeNewsWire

PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX₁₀₀ for the Prevention of Surgical Site Infection...

PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-...

1 year ago - GlobeNewsWire

PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results

•  Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval 

1 year ago - GlobeNewsWire

PolyPid to Participate in Three Upcoming Investor Conferences

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-...

1 year ago - GlobeNewsWire

PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020

PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-...

1 year ago - GlobeNewsWire